Cargando…
Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy
Nonmetastatic esophageal cancer can demonstrate a high local recurrence rate even under the standard treatment. We evaluated platelet counts before and after concurrent chemoradiotherapy (CCRT), neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio for predicting esophageal cancer prognos...
Autores principales: | Wu, Yi-Feng, Chu, Sung-Chao, Chang, Bee-Song, Cheng, Yi-Tso, Wang, Tso-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374875/ https://www.ncbi.nlm.nih.gov/pubmed/30834254 http://dx.doi.org/10.1155/2019/1263050 |
Ejemplares similares
-
Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021) -
Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers
por: Zhang, Tian-Wei, et al.
Publicado: (2023) -
Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma
por: Zhu, Shan, et al.
Publicado: (2016) -
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
por: Kim, Yong-Hyub, et al.
Publicado: (2015) -
Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
por: Yang, Xiyue, et al.
Publicado: (2021)